Atlas Venture Life Science Advisors

Latest statistics and disclosures from Atlas Venture Life Science Advisors's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are DYN, KYMR, IRON, DAWN, THRD, and represent 73.41% of Atlas Venture Life Science Advisors's stock portfolio.
  • Added to shares of these 1 stock: Q32 Bio (+$36M).
  • Started 1 new stock position in Q32 Bio.
  • Reduced shares in these 8 stocks: DYN (-$53M), DAWN (-$20M), KYMR (-$19M), IRON (-$17M), AKRO (-$8.4M), XLO, DNTH, SPRO.
  • Sold out of its position in AKRO.
  • Atlas Venture Life Science Advisors was a net seller of stock by $-85M.
  • Atlas Venture Life Science Advisors has $1.1B in assets under management (AUM), dropping by 29.03%.
  • Central Index Key (CIK): 0001917529

Tip: Access up to 7 years of quarterly data

Positions held by Atlas Venture Life Science Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors holds 16 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Dyne Therapeutics Common Stock (DYN) 21.0 $228M -18% 8.0M 28.39
 View chart
Kymera Therapeutics Common Stock (KYMR) 19.9 $216M -8% 5.4M 40.20
 View chart
Disc Medicine Common Stock (IRON) 13.1 $142M -10% 2.3M 62.26
 View chart
Day One Biopharmaceuticals Common Stock (DAWN) 9.8 $106M -15% 6.4M 16.52
 View chart
Third Harmonic Bio Common Stock (THRD) 9.5 $103M 11M 9.44
 View chart
Korro Bio Common Stock (KRRO) 9.3 $101M 1.1M 90.00
 View chart
Aerovate Therapeutics Common Stock (AVTE) 5.6 $60M 2.0M 29.57
 View chart
Q32 Bio Common Stock 3.3 $36M NEW 2.1M 17.04
 View chart
Generation Bio Common Stock (GBIO) 3.1 $34M 8.3M 4.07
 View chart
Vigil Neuroscience Common Stock (VIGL) 1.8 $20M 5.8M 3.41
 View chart
Replimune Group Common Stock (REPL) 1.6 $17M 2.1M 8.17
 View chart
Ikena Oncology Common Stock (IKNA) 0.7 $7.1M 5.0M 1.42
 View chart
AvroBio Common Stock (AVRO) 0.5 $5.8M 4.5M 1.28
 View chart
Dianthus Therapeutics Common Stock (DNTH) 0.5 $5.6M -21% 187k 30.00
 View chart
Xilio Therapeutics Common Stock (XLO) 0.1 $1.1M -64% 993k 1.08
 View chart
Spero Therapeutics Common Stock (SPRO) 0.1 $1.0M -40% 608k 1.72
 View chart

Past Filings by Atlas Venture Life Science Advisors

SEC 13F filings are viewable for Atlas Venture Life Science Advisors going back to 2022